This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights Teladoc Health, Albireo Pharma and The Joint Corp
by Zacks Equity Research
Teladoc Health, Albireo Pharma and The Joint Corp are included in this blog.
Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.
Medtronic (MDT) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.
The Joint Corp. (JYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
The Joint Corp. (JYNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q4 results are expected to gain from high sales and visits volume.
Wall Street Analysts Think The Joint Corp. (JYNT) Could Surge 84%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 84.3% upside potential for The Joint Corp. (JYNT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Mednax (MD) Pursues $1.1B Transactions to Reduce Debt Burden
by Zacks Equity Research
Mednax (MD) issues senior notes, and a new revolving credit facility coupled with a term loan remains in place, which is aimed at reducing MD's debt level and associated interest expenses.
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Molina (MOH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 2.13% and 3.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 23.29% and 7.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 0.81% and 0.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will The Joint Corp. (JYNT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
The Joint Corp. (JYNT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Joint Corp. (JYNT) Moves 9% Higher: Will This Strength Last?
by Zacks Equity Research
The Joint Corp. (JYNT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The Joint Corp. (JYNT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 225.00% and 7.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate The Joint Corp. (JYNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Should You Hold Onto Anthem (ANTM) in Your Portfolio?
by Zacks Equity Research
A solid positioning in an ever-growing industry along with strong fundamentals make Anthem (ANTM) a good fit for investment gains.
Magellan (MGLN) Unit Launches Solution to Improve Behavioral Care
by Zacks Equity Research
Magellan's (MGLN) unit - Magellan Healthcare - together with NeuroFlow, introduces a collaborative care management solution in a bid to ease the behavioral health treatment process.
Why Should You Hold Molina Healthcare (MOH) in Your Portfolio?
by Zacks Equity Research
Riding high on strategic measures and membership growth, Molina Healthcare (MOH) holds enough potential to reap benefits for investors.
Cigna's (CI) 2022 Expansion Plans to Boost MA Customer Base
by Zacks Equity Research
Cigna (CI) unveils enhanced health plans for its customers to opt for in the 2022 Medicare AEP period. The company will foray into newer counties and states to offer enhanced health outcomes.
Here's Why You Should Retain Cigna (CI) Stock for Now
by Zacks Equity Research
Cigna (CI) is benefiting on the back of robust segmental performances and well-diversified healthcare suite. A strong partner network throughout U.S. is an added advantage.
UnitedHealth (UNH) Unit to Offer Better Pharmacy Care in Arizona
by Zacks Equity Research
Genoa, which comes under UnitedHealth Group's (UNH) subsidiary Optum, opens a pharmacy in one of Arizona's clinics for offering enhanced pharmacy care for behavioral health patients.
Humana (HUM), Kelsey-Seybold Clinic Tie Up for Better Healthcare
by Zacks Equity Research
Humana (HUM) inks a deal with Kelsey-Seybold Clinic in Houston to offer its Humana Medicare Advantage HMO members enriched healthcare facilities.
Why Should You Hold Centene (CNC) in Your Portfolio Now?
by Zacks Equity Research
Riding high on strategic initiatives and operational excellence, Centene (CNC) holds potential to reap benefits for investors.
Humana (HUM), Curant Health Team Up to Aid Chronic Patients
by Zacks Equity Research
Humana (HUM) inks a deal with Curant Health to offer its members with chronic diseases enriched healthcare facilities.
Here's Why You Should Hold Molina Healthcare (MOH) Stock Now
by Zacks Equity Research
Riding high on its rising membership, a healthy revenue stream and restructuring measures, Molina Healthcare (MOH) holds potential to reap benefits for investors.